Every earnings call for LXCHEM — management tone, guidance, KPIs and promise tracking, quarter by quarter.
LXCHEM · 6 transcripts · Chemicals · latest Q4 FY26Revenue Growth (QoQ) 0.09%; Revenue Growth (FY26 YoY) -0.06% (−6% YoY); Employee Costs Increase (FY26) ₹14 cr. Q4 FY26 sequential revenue growth of 9% across both Essentials and Specialties.
Read full transcript & analysisEBITDA ₹50 cr (−33% YoY); PAT ₹25 cr (−15% YoY). PAT for Q3 FY26 stood at INR 25 crores, down from INR 29.3 crores in the previous year.
Read full transcript & analysisTotal Revenue ₹808 cr (−9% YoY); EBITDA ₹37 cr (−50% YoY); EBITDA Margin 5.3%. Total revenue declined by 9% YoY to approximately INR 807.6 crores in Q2 FY26.
Read full transcript & analysisPAT ₹21 cr (−38% YoY); PAT Margin 3.1%. Overall revenue de-grew by nearly 4% in Q1 FY26, despite an 8% volume growth.
Read full transcript & analysisAdjusted EBITDA (Q4 FY25) 590 million; EBITDA Margin (FY25) 9.4%; PAT Margin (FY25) 3.8%. Full year FY25 volume growth was 11% overall, with specialty chemicals growing 7% and essentials (acetyls) at 12.5%.
Read full transcript & analysisEBITDA ₹75 cr (+241% YoY); Gross Margin 33.1%. Sales grew 13% year-on-year in Q3 FY25.
Read full transcript & analysis